Integrating Prostate Health Index with mpMRI for Diagnosing Significant Prostate Cancer in Asians

Overview

This study evaluated the combined use of Prostate Health Index (PHI) and multiparametric MRI (mpMRI) for detecting clinically significant prostate cancer (csPC) in an Asian population. The integration of PHI and mpMRI improved diagnostic accuracy and may reduce unnecessary biopsies.

Background

Prostate cancer incidence is rising in Asia, partly due to aging populations and Westernized lifestyles. Serum prostate-specific antigen (PSA) screening has limitations in specificity, leading to unnecessary biopsies. PHI, combining p2PSA, free PSA, and total PSA, has shown better predictive value for csPC. mpMRI with PI-RADS v2 scoring is a valuable imaging tool to identify suspicious lesions and guide biopsies. Combining PHI and mpMRI may enhance csPC detection, but data in Asian populations are limited.

Data Highlights

Key Findings

• PHI outperforms total and free PSA in detecting clinically significant prostate cancer in both initial and repeat biopsy settings.
• mpMRI using PI-RADS v2 shows high sensitivity (89%) and moderate specificity (73%) for csPC detection.
• Combining PHI and mpMRI improves diagnostic accuracy beyond either modality alone in an Asian cohort.
• Use of mpMRI can help avoid approximately 27% of unnecessary prostate biopsies.
• PHI ≥ 30 was selected as a diagnostic cutoff based on meta-analysis data in Asian populations.
• Targeted biopsy guided by mpMRI lesions (PI-RADS ≥ 3) combined with systematic biopsy enhances detection of csPC.

Clinical Implications

Integrating PHI testing with mpMRI assessment can improve the identification of clinically significant prostate cancer and reduce unnecessary biopsies in Asian patients with elevated PSA or abnormal digital rectal exam. This combined approach may optimize patient selection for biopsy, minimizing procedure-related complications and healthcare costs. Clinicians should consider adopting PHI and mpMRI in diagnostic pathways where available and feasible.

Conclusion

The combination of Prostate Health Index and multiparametric MRI enhances the detection of clinically significant prostate cancer in Asian populations, offering a promising strategy to improve diagnostic precision and reduce unnecessary biopsies.

References

1. Global cancer statistics and prostate cancer incidence trends
2. PHI and mpMRI diagnostic performance studies
3. PI-RADS v2 guidelines and meta-analysis on mpMRI accuracy
4. Standards of Reporting for MRI-Targeted Biopsy Studies (START) guidelines